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Key messages
What is already known about this subject?
 ► randomised controlled clinical trials have already 
shown that the concomitant use of methotrexate 
(MtX) in patients with rheumatoid arthritis (ra) on 
biologics is more efficient compared with monother-
apy with biologics.
What does this study add?
 ► Observational studies in ra investigating the add-
ed value of concomitant MtX over monotherapy 
with biologicals are scarce and yield contradictory 
conclusions.
 ► this study adds to the knowledge that cotreatment 
with MtX in routine care patients with ra treated 
with biologicals lowers 28-joint Disease activity 
Score (DaS28) over time and improves the likelihood 
to be in DaS28 remission.
 ► Benefits were detected in non-patient-reported dis-
ease aspects like the swollen joint count instead of 
patient-reported aspects of the routine assessment 
of Patient index Data 3(raPiD3).
How might this impact on clinical practice?
 ► By demonstrating the clinical significance of con-
comitant MtX use in routine care patients with ra, 
rheumatologists are helped with motivating patients 
to continue to use MtX combined with a biological in 
accordance with the treatment guidelines.
AbstrAct
Objectives We aimed to evaluate the effects of 
methotrexate (MtX) comedication added to biological 
disease-modifying antirheumatic drugs (bDMarD) on 
disease activity measures in patients with rheumatoid 
arthritis (ra) in routine care.
Methods Patients with ra on treatment with either 
bDMarDs or conventional synthetic DMarDs were 
included in this prospective cohort study. the effect of 
(time-varying) combination therapy with bDMarD and 
MtX compared with bDMarD monotherapy was tested 
in longitudinal generalised estimating equation models 
using as outcomes: (1) the likelihood to be in remission 
according to the 28-joint Disease activity Score (DaS28) 
erythrocyte sedimentation rate (eSr) (<2.6) and to the 
routine assessment of Patient index Data 3 (raPiD3) 
(0–30; ≤3), a patient-reported outcome measure about ra 
symptoms; and (2) DaS28-eSr and raPiD3 as continuous 
variables. all models were adjusted for potential 
confounders: age, gender, drugs for comorbidities (yes/no), 
oral steroids (yes/no) and non-steroidal anti-inflammatory 
drug (yes/no).
Results in total, 330 patients were included (mean 
(SD) follow-up; 10.7 (9.7) months). compared with 
bDMarD monotherapy, MtX combination therapy was 
significantly associated with a 55% higher likelihood to be 
in DaS28 remission, but not raPiD3 remission, over time. 
combination therapy resulted in slightly, but statistically 
significant, lower levels of DaS28-eSr over time (β=−0.42 
(95% ci −0.67 to − 0.17)), but not raPiD3 (β=−0.58 (95% 
ci −0.65 to 0.49)). the effect on DaS28-eSr was entirely 
explained by lower swollen joint counts and was persistent 
after correction for confounders.
Conclusion these results give support to the policy that 
MtX should be continued in routine care patients with ra 
on biological therapy since this leads to better objective 
but not subjective clinical outcomes
InTROduCTIOn
Concomitant use of methotrexate (MTX) 
in patients with rheumatoid arthritis (RA) 
treated with biological disease-modifying anti-
rheumatic drugs (bDMARD) has been shown 
to be more efficacious in mitigating these 
manifestations as compared with bDMARD 
monotherapy in various randomised clinical 
trials (RCT).1–4 The European League Against 
Rheumatism and the American College of 
Rheumatology (ACR) have recommended 
this strategy.3 4
Still, there is evidence that many rheuma-
tologists do not adhere to a strategy of MTX 
added to bDMARD in daily clinical prac-
tice.5 6 There are several reasons to explain 
non-adherence, such as poor tolerability 
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Table 1 Baseline characteristics comparing patients treated and not treated with MTX at baseline
All patients
(n=330)
MTX at baseline
(n=148)
No MTX at baseline
(n=182) P value*
Female gender, n (%) 224 (67.9) 95 (64.2) 129 (70.9) 0.200
Age (years), mean (SD) 62.0 (11.6) 63.4 (11.6) 60.9 (11.4) 0.054
Disease duration (years), mean (SD) 11.2 (9.6) 9.3 (7.8) 12.9 (10.3) 0.007
ESR, mean (SD)† 18.7 (17.6) 19.3 (16.8) 18.1 (18.5) 0.60
SJC (0–28), mean (SD)† 2.3 (3.5) 1.5 (2.7) 3.2 (3.9) <0.001
TJC (0–28), mean (SD)† 4.1 (5.5) 3.0 (5.1) 5.2 (5.8) 0.004
DAS28-ESR, mean (SD) 3.3 (1.4) 3.1 (1.3) 3.5 (1.4) 0.001
RAPID3 total score (0–30), mean (SD) 11.5 (6.2) 10.1 (6.2) 12.6 (6.0) <0.001
RAPID3 function (0–10), mean (SD) 2.5 (1.9) 2.1 (1.8) 2.8 (2.0) <0.001
VAS pain (0–10), mean (SD) 4.3 (2.6) 3.9 (2.5) 4.7 (2.5) 0.004
PGA (0–10), mean (SD) 4.7 (2.4) 4.2 (2.5) 5.1 (2.4) <0.001
n drugs for comorbidities, mean (SD) 1.1 (1.7) 1.2 (1.8) 1.0 (1.7) 0.390
≥1 drug for comorbidities, n (%) 137 (41.5) 56 (37.8) 81 (44.5) 0.220
NSAIDs, n (%) 130 (39.4) 53 (35.8) 77 (42.3) 0.230
Oral steroids, n (%) 117 (35.5) 51 (34.5) 66 (36.3) 0.730
MTX dosage, median (IQR), mg/week‡ – 15 (10–20) –
bDMARDs, n (%)
  No bDMARD§ 104 (31.5) 77 (52.0) 27 (14.8)
  TNFi¶ 185 (56.1) 62 (41.9) 123 (67.6) <0.001
  No TNFi ** 41 (12.4) 9 (6.1) 32 (17.6)
*χ2 test for categorical variables; independent samples t-test for continuous variables, statistical significant differences between treated and 
not treated with MTX at baseline are shown in bold
†n=213 patients. n (%) for categorical variables. Mean±SDs are presented above for normally distributed variables.
‡Subcutaneous MTX was used in 15% of the cases where MTX was used.
§Patients (n=27) neither on bDMARDs nor on MTX were treated with leflunomide, sulfasalazine or hydroxychloroquine.
¶TNFi includes: etanercept, infliximab, adalimumab, certolizumab pegol, golimumab.
**No TNFi includes: rituximab, abatacept, tocilizumab.
DAS28-ESR, 28-joint Disease Activity Score (four variables, ESR based); ESR, erythrocyte sedimentation rate; MTX, methotrexate; NSAID, 
non-steroidal anti-inflammatory drug; PGA, patient global assessment; RAPID3, Routine Assessment of Patient Index Data 3; SJC, swollen 
joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitors; VAS, visual analogue scale; bDMARD, biological disease-
modifying antirheumatic drug.
and emerging contraindications,6 7 but this points to a 
discrepancy between clinical trials and usual practice. In 
fact, while RCT data on the efficacy of MTX added to 
bDMARD therapy are convincingly positive, evidence of 
such an effect in daily clinical practice is still scarce.
A few observational studies tried to bridge the findings 
in real-world clinical practice and RCTs on the efficacy 
data of bDMARDs in general.8–12 Thus far, observational 
research has yielded conflicting results regarding the 
possible added benefits of MTX on patients receiving 
bDMARDs and studies using longitudinal data are 
lacking.9 12 In this study, we aimed to evaluate the longi-
tudinal effect of combining MTX with bDMARDs on 
disease activity measures over time in patients with RA 
from daily clinical practice.
PaTIenTs and MeTHOds
Patients
Consecutive adult patients with a clinical diagnosis 
of RA according to their treating rheumatologist that 
also fulfilled the ACR 1987 classification criteria13 were 
treated with conventional synthetic DMARD and/or 
bDMARDs. These patients were included in this prospec-
tive observational study that was executed in a large 
rheumatology centre in the Netherlands between April 
2013 and April 2016. The local medical ethics committee 
reviewed and approved the study protocol. All patients 
provided informed consent before inclusion and were 
treated according to the routine care schedule.
data collection
Patient’s age, gender, disease duration (in years) and 
the number of previous bDMARD failures (if any) 
were assessed at baseline. Data on disease activity meas-
ures, laboratory parameters and medication status were 
collected during routine visits every 3 months by rheuma-
tologists and research nurses. A 28-joint Disease Activity 
Score (DAS28) based on four variables (tender joint 
count (TJC), swollen joint count (SJC), patient global 
assessment (PGA), erythrocyte sedimentation rate (ESR) 
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Figure 1 Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori 
adjusted for possible confounders: age, gender, drugs for comorbidities (1/0), oral glucocorticosteroids (1/0) and use of non-
steroidal anti-inflammatory drugs. *Number of patients per visit. bDMARD, biological disease-modifying antirheumatic drug; 
DAS28, 28-joint Disease Activity Score; MTX, methotrexate; RAPID3 (0–30), Routine Assessment of Patient Index Data (three 
domains: functioning, pain, patient global)
based (DAS28-ESR)) and Routine Assessment of Patient 
Index Data 3 (RAPID3) were used in this study to reflect 
daily clinical practice.14 15 RAPID3 is a patient-driven 
questionnaire for RA outcome reporting on functioning 
(0–10), pain (0–10) and global health (0–10). RAPID3 
(0–30) scores of >12, 6.1–12, 3.1–6 and ≤3 give high, 
moderate and low disease activity and remission, respec-
tively. Prescription of comedication was used as a proxy 
for the presence of comorbidities and was collected 
using the Anatomical Therapeutic Chemical (ATC) 
Classification System for the most frequently reported 
indications,16 namely cardiovascular diseases (ATC C*), 
type 2 diabetes mellitus (ATC C10*), chronic obstructive 
pulmonary disease and asthma (ATC R03*).17
statistical analysis
The effect of combination treatment with MTX and 
bDMARDs as compared with bDMARD monotherapy on 
disease activity measures over time was tested in longi-
tudinal linear/binomial (depending on the outcome) 
generalised estimating equation models with both the 
treatment and the outcome modelled as time-varying vari-
ables. Treatment was added to the models as a ‘dummy’ 
variable reflecting the four options encountered in clin-
ical practice: (1) bDMARD+MTX; (2) bDMARD alone 
(reference); (3) MTX alone; and (4) none, but analyses 
focused on the comparison of interest (ie, combination 
treatment vs bDMARD monotherapy). The exchange-
able ‘working’ correlation structure was used to take into 
account the repeated measures over time within patients. 
Disease activity was modelled in three complementary 
ways: (1) DAS28 and RAPID3 as continuous variables; (2) 
DAS28 and RAPID3 as binary definitions of remission 
(ie, <2.6 and ≤3, respectively); and (3) individual DAS28 
components: that is, TJC (0–28), SJC (0–28), PGA (0–10) 
and ESR (mm/hour) as continuous variables. The effects 
of treatment on each outcome were tested in separate 
models, first with no adjustment (‘crude model’), and 
second after adjustment for variables a priori selected on 
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clinical grounds as potential confounders (age (years), 
gender, use of drugs for comorbidities (yes/no), oral 
glucocorticoids (yes/no) and use of non-steroidal anti-in-
flammatory drugs (NSAID; yes/no)). Variables that vary 
over time (eg, treatment with NSAIDs) were modelled as 
such. All analyses were done with Stata V.15.
ResulTs
Patients and follow-up
In total, 330 patients (1348 visits) were included. Overall, 
the mean (SD) follow-up time was 10.7 (9.7) months. The 
mean (SD) overall disease duration at baseline was 11.2 
(9.6) years and failure of at least one previous bDMARD 
occurred in 20% of the patients. Patients on MTX come-
dication, compared with patients not on MTX, had at 
baseline lower mean DAS28-ESR (3.1 (1.3) with MTX 
vs 3.5 (1.4) without MTX; p=0.001) and lower RAPID3 
scores (10.1 (6.2) with MTX vs 12.6 (6.0) without MTX; 
p<0.001). Other demographic and disease characteristics 
comparing the two groups are described in table 1.
longitudinal effect of combination therapy versus bdMaRd 
monotherapy on disease activity over time
Overall, the adjusted estimates of the mean disease activity 
measured by DAS28 and RAPID3 over time are depicted 
in figure 1. MTX use in combination with bDMARDs 
was associated with lower levels of DAS28 compared with 
bDMARD monotherapy over time. On average, patients 
on combination treatment over time had 0.4 unit lower 
DAS28 than those treated with only bDMARDs, a small, 
yet statistically significant, difference that persisted after 
adjustment for age and other confounders (table 2).
This benefit of MTX comedication was also seen with 
regard to the likelihood of achieving DAS28 remission, 
which was on average 55% higher with combination treat-
ment. When looking into DAS28 individual components, 
the added benefit of MTX could only be demonstrated 
for the SJC but not for the ESR, TJC and PGA. RAPID3, 
both as a continuous variable and as a binary definition 
of remission, was not significantly different between the 
two different treatment strategies (table 2).
dIsCussIOn
In this prospective observational study we have shown 
that bDMARD patients with RA on MTX comedication 
fare objectively better than those on bDMARD mono-
therapy. This benefit was entirely explained by lower 
SJCs and did not extend to patient-reported measures 
of disease activity (RAPID3), nor to ESR and TJC, which 
adds to the recent suggestion that objectively measured 
and patient-reported outcomes should be separated 
when judging treatment effectiveness.18 19
Previous observational studies assessing the possible 
benefits/hazards of maintaining combination therapy 
in RA have yielded conflicting results. Gabay et al9 have 
shown that on average DAS28 was lower with combina-
tion treatment compared with bDMARD monotherapy, 
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up to 4 years of follow-up. However, the same study has 
also shown no meaningful differences between the two 
strategies on the likelihood of being in DAS28 remis-
sion. Listing et al12 have previously shown a comparable 
result for combination versus monotherapy in a prospec-
tive study from the German biologics registerR. Other 
studies are less informative due to their cross-sectional 
design.8 9 Our study includes several paired measure-
ments of DAS28 and RAPID3 collected over time in the 
same patients, and allows a better estimation of the long-
term benefit of bDMARD therapy plus MTX comedica-
tion versus bDMARD therapy alone.
Of note, the positive effects of MTX comedication on 
disease activity measures were still present when taking 
into account the patients’ comorbidities, age, treatment 
with NSAIDs and oral glucocorticoids (ie, factors that 
might confound the association of interest). This finding 
further argues in favour of combination treatment even 
in more complex patients with comorbidities and long 
disease duration.
Interestingly, the effect of combination therapy on 
disease activity was only detected when using DAS28, but 
not RAPID3. Also, when looking at the various individual 
components of DAS28, the positive effect was only seen on 
the number of swollen joints (ie, an objective measure). 
This finding suggests that objective clinical outcome 
measures have merits in demonstrating treatment effects 
in daily clinical practice, and that only measuring subjec-
tive, patient-reported aspects of the disease, as is done 
with RAPID3, does not suffice despite strong messages 
by advocates.
Our study has some limitations worth noticing. The 
most important one is the expected a priori prognostic 
dissimilarity that may drive differences between the two 
strategies (confounding by indication). Among others, 
patients who are on MTX since they tolerate it may have 
better prognosis and thus better response to therapy. 
Tapering or discontinuation of bDMARD therapy in 
these patients could be considered. However, this is a 
common issue of all observational studies, that is, increase 
external validity (patients from clinical practice in whom, 
for example, comorbidities may have impaired cotreat-
ment with MTX), at the cost of the internal validity (lack 
of random and blinded treatment allocation). Second, 
residual confounding cannot be completely ruled out, 
nevertheless after the adjustment for, arguably, the most 
important confounders the effect of MTX was still consis-
tently seen in all models.
In conclusion, our results show patients with RA on 
biological therapy who have maintained their MTX dose 
have lower disease activity because they have less swollen 
joints.
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